Advanced Proteome Therapeutics Corp.

Recent News

  • Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire

    Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.APTI is pleased to report that Dr. Ravi Chari is joining the Company's Scientific Advisory Board and Dr. Rajeshkumar Manian is joining as the lead organic chemist. Dr. Chari has over 30 years of...

    2021-06-09 1:40 PM EDT
  • Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-Brokered Private Placement

    Burnaby, British Columbia--(Newsfile Corp. - April 13, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the final tranche of its non-brokered private placement (the "Private Placement") raising gross proceeds of $524,610 by the issuance of 2,559,073 units at a price of $0.205 per unit.Each unit consists of one...

    2021-04-13 5:12 PM EDT
  • Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has increased its previously announced private placement financing (see March 1st, 2021 news release) from up to 6,097,561 units of the Company ("units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one...

    2021-03-11 1:38 PM EST
  • Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 1, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") announces that, subject to the approval of the TSX Venture Exchange (the "Exchange"), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant...

    2021-03-01 1:11 PM EST
  • Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO

    Burnaby, British Columbia--(Newsfile Corp. - December 17, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company'), is pleased to announce that Dr. Benjamin Krantz will be joining the Company's US subsidiary Advanced Proteome Therapeutics Inc. ("APTI") as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors...

    2020-12-17 1:02 PM EST
  • Advanced Proteome Therapeutics Provides Project Update

    Vancouver, British Columbia--(Newsfile Corp. - August 14, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is rapidly advancing three projects with the potential to add significant shareholder value.As previously announced, APTI's scientists have identified multiple compounds with high predicted affinity for the SARS-CoV-2 main protease that exceed the affinity of all published candidate viral protease inhibitors known to APTI. APTI has filed patents...

    2020-08-14 10:45 AM EDT
  • Advanced Proteome Therapeutics Files Provisional IP for Compounds Targeting SARS-CoV-2

    Burnaby, British Columbia--(Newsfile Corp. - July 9, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has filed for patent protection on a family of therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19 and has initiated a project to rapidly manufacture test quantities of these drugs. As previously announced, APTI's scientists have identified multiple compounds with predicted affinity for the SARS-CoV-2...

    2020-07-09 3:23 PM EDT